MedTrace Logo

Cognitive Effects of Immunomodulatory Drugs in MS

NCT00229502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96

Last updated 2012-03-23

No results posted yet for this study

Summary

The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Conditions

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • Sharon Lynch, MD

    lead OTHER

Principal Investigators

  • Sharon G Lynch, MD · University of Kansas Medical Center

  • Douglas R Denney, PhD · University of Kansas Medical Center

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00229502 on ClinicalTrials.gov